We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Mobile DNA Test Developed for HIV

By LabMedica International staff writers
Posted on 19 Jun 2014
An efficient test to detect signs of human immunodeficiency virus (HIV) and its progress in patients in low-resource settings is being developed using recombinase polymerase amplification (RPA). More...


The current gold standard to diagnose HIV in infants and to monitor viral load depends on laboratory equipment and technical expertise generally available only in clinics, while the new assay features a nucleic acid-based test that can be performed at the site of care.

Bioengineers at Rice University (Houston, TX, USA) developed a new technique that would replace a complex procedure based on polymerase chain reaction (PCR) with one that relies on RPA, a method that quickly amplifies genetic markers found in blood to levels where they can be easily counted. In the test the team calls quantitative RPA (qRPA), a specific sequence in HIV DNA is targeted and tagged with fluorescent probes that can be seen and quantified by a portable machine. Software analysis of the fluorescing DNA allows clinicians to determine with great accuracy whether the virus is present in a patient's blood and/or how much is there.

Amplification and real-time data collection were performed in a CFX96 Real Time qPCR machine (Bio-Rad; Hercules, CA, USA). Preliminary RPA experiments detecting HIV-1 DNA and internal positive control sequence (IPC) DNA in separate reactions demonstrated that the time at which detectable amplification begins, increases with decreasing DNA concentration, suggesting that quantification of DNA with RPA is feasible. The assay could potentially be optimized for greater accuracy by collecting fluorescence data more frequently or decreasing the reaction rate by either decreasing the concentration of magnesium acetate in the reaction or amplifying at a lower temperature.

This assay was designed for use with an inexpensive, point-of-care fluorescence reader, such as the commercially available Twista portable real-time fluorometer (TwistDx, Ltd.; Cambridge, UK) or the ESEQuant Tube Scanner (Qiagen; Valencia, CA, USA). To be clinically viable, a DNA-based test for HIV has to be able to quantify virus loads over four orders of magnitude, from very low to very high; the scientists reported that the qRPA test easily meets that goal. The study was published on May 26, 2014, in the journal Analytical Chemistry.

Related Links:

Rice University
Bio-Rad
TwistDx Ltd.




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.